{
  "catalogId": "bff7c5fb-f10b-408f-b241-b4601e1a4a07",
  "name": "SIMPONI",
  "status": "",
  "category": "prescription",
  "registrationValidity": "valid",
  "registrationNumber": "147 32 33213 00",
  "treatmentDescriptions": "Rheumatoid Arthritis:Simponi, in combination with methotrexate, is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis when the response to disease-modifying anti-rheumatic drug (DMARD) therapy including MTX has been inadequate.Juvenile idiopathic arthritis: Polyarticular juvenile idiopathic arthritis (pJIA)Simponi in combination with MTX is indicated for the treatment of polyarticular juvenile idiopathic arthritis in children with a body weight of at least 40 kg, who have responded inadequately to previous therapy with MTX.Simponi 100 mg is not recommended in children aged less than 18.Psoriatic Arthritis:Simponi, alone or in combination with methotrexate, is indicated for the treatment of adult patients with active and progressive  psoriatic arthritis when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate.Axial spondyloarthritis:* Ankylosing SpondylitisSimponi is indicated for the treatment of adult patients with severe active ankylosing spondylitis who have responded inadequately to conventional therapy.* Non-radiographic axial spondyloarthritis (nr-Axial SpA)Simponi is indicated for the treatment of adults with severe, active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDS).Ulcerative colitis (UC):Simponi is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.",
  "termsOfIssue": "Prescription required",
  "form": "solution for injection",
  "route": "s.c",
  "site": "",
  "method": "",
  "administrationNotes": "",
  "ingredients": "GOLIMUMAB/ML",
  "codes": {
    "atc5": {
      "system": "WHO ATC Classification",
      "code": "L04AB06",
      "name": "GOLIMUMAB"
    }
  },
  "contraindications": "",
  "sideEffect": "",
  "warnings": "",
  "alternativeMedications": [],
  "packaging": [
    {
      "name": "SIMPONI 50MG/0.5ML (0.5ML) PREFILLED PEN",
      "manufacturer": {
        "name": "יאנסן סילג",
        "countryOfOrigin": "IL"
      },
      "strength": {
        "value": 0,
        "unit": ""
      },
      "quantity": {
        "value": 1.0,
        "unit": "units"
      },
      "packagingDescription": "AUTO - INJECTOR PEN GLASS TYPE I",
      "shelfLife": "24",
      "storageConditions": "",
      "codes": {
        "moh": "6698",
        "yarpa": "29028",
        "pharmasoft": "6698",
        "barcode": "7290014577299"
      },
      "manufacturersAdministrationRecommendation": "",
      "pricing": {
        "currency": "ILS",
        "maxWholesalePrice": 3027.505637,
        "retailMargin": 10.0,
        "maxRetailPrice": 3330.256201,
        "maxPriceWithVAT": 3929.702142
      }
    }
  ],
  "metadata": {
    "version": "1.4",
    "lastUpdated": "2025-07-31T08:13:48.907402"
  }
}